trial

Learning and Executive Function Disorders in Children and Psychosis Risk at Adult-age

NCTId NCT04280367
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 20 (actual)
Sponsored by Assistance Publique - Hôpitaux de Paris
Primary completion 2020-05-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
20 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2020-01-28
Primary completion
2020-05-29
Eligibility
ALL · 15 Years · 30 Years

Interventions & indications

Drugs
Standardised semi-structured talkAutistic spectre disorder screeningAnxiety measuring

Sponsors

Assistance Publique - Hôpitaux de ParisLead Sponsor

Investigators

2
Emilie SCHLUMBERGER, MDPrincipal Investigator
Albane MansouxStudy Director

Sites

1 total
Garches, France

Facts & assertions

4 sourced
Enrollment
20
Phase
NA
Primary Completion Date
2020-05-29
Status
COMPLETED
relationships
The graph out of here
drug
Standardised semi-structured talk
drug
Autistic spectre disorder screening
drug
Anxiety measuring
drug
lead_sponsor
Assistance Publique - Hôpitaux de Paris
company
indication
Learning Disorders
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Emilie SCHLUMBERGER, MD
person
Albane Mansoux
person